C9ORF72 ZFP-TF gene therapy (Sangamo/Pfizer)

N/A

Report date: 2025/03/14 16:37:29

Base Information

Drug NameC9ORF72 ZFP-TF gene therapy (Sangamo/Pfizer)
Drug Alias Nameamylotrophic lateral sclerosis gene therapy (Pfizer)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionGuanine nucleotide exchange C9orf72 inhibitors
TargetsGuanine nucleotide exchange C9orf72
Therapy Area/IndicationsAmyotrophic Lateral SclerosisFrontotemporal Dementia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncSangamo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisFrontotemporal Dementia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A